Congo's deadliest Ebola: 2,325 dead - critical summary review

Ebola has been spreading in the Democratic Republic of the Congo since February. The country only declared the outbreak on 15 May. On 17 August it became the deadliest epidemic in Congolese history, and the World Health Organization says that at its current pace it could overtake the 2014-2016 West Africa outbreak, the largest ever recorded. What follows is what happened, and why the response keeps arriving after the virus.

The record that fell on 17 August

Congo's National Public Health Institute reported 2,325 deaths and 4,945 confirmed cases, including 101 detected in a single 24-hour period. That death toll passed the 2,299 recorded in the 2018-2020 outbreak in the country's east, which had been its worst — and which took roughly two years to get there.

The speed is the part health officials keep returning to. It took almost five months for the 2014-2016 West Africa outbreak to reach 1,000 deaths; this one passed 2,000 in under three months. According to the Africa CDC, the African Union's public health agency, the first months of the Congolese outbreak produced seven times more infections and five times more deaths than the first three months of the West African one. That epidemic, across Guinea, Liberia and Sierra Leone, ended with 28,616 cases and more than 11,000 deaths — the benchmark this outbreak is now measured against.

Six of Congo's 26 provinces have been affected, mostly along the north-eastern border. More than 3,400 cases are in Ituri, where it started. The sixth province, Bas-Uele, was added in mid-August after a man died in its capital, Buta, having travelled from Haut-Uele.

A strain with no vaccine

Four types of Ebola virus infect humans: Zaire, Sudan, Bundibugyo and Tai Forest. This outbreak is Bundibugyo, which had caused only two known outbreaks before, in 2007 and 2012. There is no approved vaccine and no approved treatment for it. The vaccine developed after 2014 works against the Zaire strain.

A study published in Nature Medicine, a peer-reviewed medical journal, sequenced virus samples from 22 patients in Congo and Uganda and found the outbreak strain genetically distinct from the earlier Bundibugyo viruses — evidence that it began with a fresh jump from an animal reservoir into a person, then spread person to person.

Krutika Kuppalli, an infectious diseases doctor with experience in outbreak response, said the animal origin does not make the virus intrinsically more dangerous, and does not change how patients are treated. What matters clinically, she said, is that Bundibugyo "currently does not have the same licensed, proven virus-specific therapeutics that we have for Zaire ebolavirus". Care is supportive: fluids, electrolytes, treating shock and organ failure.

Why more patients are dying, not fewer

The case fatality ratio — the share of confirmed patients who die — has risen from about 20% in early June to 46%. Nearly one in two confirmed cases now ends in death.

Experts quoted by the agencies say this is not a sign the virus has become more lethal. It points instead to surveillance, detection and access to care. Thomas Parisch, a public health specialist deployed to Congo with Médecins Sans Frontières, the international medical charity known in English as Doctors Without Borders, put it this way: "Normally, as an outbreak progresses, the case fatality ratio should fall as contact tracing improves and patients are identified and treated earlier. Instead, we're still seeing many cases detected very late, when treatment is less likely to succeed, with many identified only after they die in the community."

More than 70% of deaths happen in the community rather than in treatment centres, said Mohamed Janabi, the WHO's regional director for Africa, who also estimated that health workers are reaching only about 30% of cases. Between 60% and 70% of new cases are found outside the contact lists being monitored. Sylvie Briand, the WHO's chief scientist, said no mutations have been observed in this outbreak; Jean Kaseya, head of the Africa CDC, said officials were nonetheless worried the virus could be mutating and planned further studies with the WHO.

Conflict, strikes, funerals and mistrust

The outbreak is centred on a mineral-rich region contested by armed groups. Almost a million people in Ituri have been displaced by conflict, according to the UN's humanitarian office. It has also spread south into parts of North Kivu and South Kivu held by the M23 rebel group.

Response teams face attacks on health facilities, often triggered by misinformation about burial practices, and open-casket family funerals that raise the risk of transmission. Health workers at the treatment centre in Nizi, in Ituri, went on strike after three months without pay, temporarily closing it. More than 100 health workers have been infected and about 35 have died. Humanitarian funding for Congo fell sharply in 2025, largely after the Trump administration froze foreign aid channelled through the State Department. To break transmission chains, 95% of contacts need to be traced; the rate is around 80%.

Distrust does the rest. In the Djugu area of Ituri, Jean-Paul Malo Lotsima, a civil society official, said people "prefer to be treated at home, thinking it is a case of poisoning or some other illness" and are taken to hospital "at the last minute, when the family realises that the situation is getting worse. And sometimes, they die on the way." Flavier Ngurima, from the hotspot of Nizi, said his brother died before reaching a treatment centre: the family called a nurse to the house because they were afraid of the centre. "They said that over there, a lot of people die."

Detection itself was late. The earliest known suspected victim, a 59-year-old man, fell ill on 24 April and died three days later; authorities were alerted through social media on 5 May, by which point the Africa CDC says 50 people had already died. Early cases were attributed to malaria and typhoid, and initial testing looked for the more common Zaire strain.

What is being tested against the clock

Clinical trials of two existing antiviral treatments began in July in Ituri, sponsored by the WHO, to see whether they improve survival. Tedros Adhanom Ghebreyesus, the WHO director-general, said in mid-August that two vaccines developed specifically for Bundibugyo were being tested in people for the first time. One comes from a University of Oxford team using the same technology as the Oxford-AstraZeneca Covid vaccine; the UK's medicines regulator, the MHRA, cleared the first human trials. Three other groups are developing Bundibugyo vaccines that have not yet entered clinical trials.

Separately, the WHO recommended a full-scale human trial of Ervebo, the licensed vaccine that works against the Zaire strain. Its effect on Bundibugyo is unproven, with evidence so far limited to animal studies that officials described as promising. Gavi, the global vaccine alliance, has made about 500,000 stockpiled doses available for the trial.

Why the risk far from Africa stays low

Ebola spreads through direct contact with the bodily fluids of infected people, living or dead, and with contaminated surfaces and materials such as bedding and clothing. "It doesn't travel across the air and across a room," said David Wohl, a professor of medicine in the division of infectious diseases at the University of North Carolina at Chapel Hill, who called the current situation "a fire that's raging". He also noted that during the 2014-2016 outbreak, with more than 28,000 infections, only four Ebola cases were diagnosed in the United States — two imported, and two nurses infected while caring for a patient in Dallas.

Exported cases in this outbreak have been few. Uganda recorded 20, all in Kampala, with two deaths, and was declared Ebola-free on 28 July. Two people were treated in Germany, and France reported one case with no secondary transmission after the patient was discharged on 4 July.

What to do with this information

Three concrete markers are worth watching over the coming weeks. First, the curve. Abdirahman Mahamud, head of the WHO's emergency response division, said that if the response is implemented simultaneously across the five transmission zones, a turnaround could be expected within three months — which is not the same as the outbreak ending. Under a moderate scenario it peaks in six months; it could run nine to 12. The number to watch against that promise is 28,616, the case count of the 2014-2016 outbreak: pass it and this becomes the largest in the disease's known history.

Second, the trials. Results from the first human tests of the Bundibugyo-specific vaccines, and from the Ervebo trial, will determine whether there is any real containment tool available in the coming months rather than only supportive care.

Third, geography. Six provinces are affected; the concern raised in Kinshasa, a city of 19 million with no recorded case so far, is preventive. Jean-Jacques Muyembe, head of Congo's National Institute for Biomedical Research, said the capital is prepared to identify and isolate cases quickly. Cinquantenaire Hospital has set up 20 beds, expandable to 200 or 250 according to its coordinator, Christian Ngandu; the WHO has said several thousand beds would be needed in a worst-case scenario, and Carlos Mupili, president of the Supreme Council of Civil Society, called current capacity insufficient.

If you live outside the region, the practical step is not domestic contagion, which the infectious disease specialists quoted here rule out. It is checking travel rules before any trip to Congo, Uganda or neighbouring countries. Rwanda has barred foreign travellers who were in Congo in the previous 30 days; Bahrain suspended entry for 30 days for foreign travellers from South Sudan, Congo and Uganda; the United States has said travellers who have been in Congo within 21 days of departure will not be allowed to board commercial flights to US destinations. Governments across Asia have started border screening. These rules have been changing as the outbreak moves.